Capítulo 9: Nefrotoxicidad por fármacos
DOI:
https://doi.org/10.47196/diab.v58i2Sup.792Palabras clave:
nefrotoxicidad inducida por fármacos, enfermedad renal, diabetes mellitusResumen
La nefrotoxicidad inducida por fármacos, también denominada enfermedad renal inducida por fármacos (ERIF), afecta entre el 14% y el 26% de los pacientes adultos y a el 16% de los pacientes pediátricos. Sin embargo, la incidencia de ERIF puede llegar al 66%. Entre los adultos mayores la incidencia es mayor, puesto que estos se caracterizan por presentar múltiples enfermedades, la polifarmacia y, por lo tanto, están sujetos a procedimientos diagnósticos y terapéuticos que pueden dañar los riñones. La disfunción renal suele ser reversible al suspender el fármaco causante; sin embargo, puede producir daño estructural irreversible. La nefrotoxicidad se manifiesta en un amplio espectro, reflejando daño en diferentes segmentos de la nefrona, incluidos los segmentos glomerulares y tubulares.
Citas
I. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008;78:743-750.
II. Awdishu L, Mehta RL. The 6R’s of drug induced nephrotoxicity. BMC Nephrol 2017; 18:124. doi: 10.1186/s12882-017-0536-3.
III. Mehta RL Awdishu L, Davenport A, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int 2015; 88:226-234.
IV. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:8-138.
V. Dobrek LA. Synopsis of current theories on drug-induced nephrotoxicity. Life (Basel) 2023 Jan 24;13(2):325.
VI. Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med 2019 May 30; 380(22):2146-2155.
VII. Chaudhari H, Mahendrakar S, Baskin SE, Reddi AS. Contrast-induced acute kidney injury: evidence in support of its existence and a review of its pathogenesis and management. Int J Nephrol Renovasc Dis 2022 Oct 11; 15:253-266.
VIII. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium. Precipitation within the kidney. Clin Sci (Lond) 2004;106(6):549-561.
IX. Hsu HJ, Wu MS. Extreme hyperphosphatemia and hypocalcemic coma associated with phosphate enema. Intern Med 2008;47(7):643-646
X. Schaefer M, Littrell E, Khan A, et al. Estimated GFR decline following sodium phosphate enemas versus polyethylene glycol for screening colonoscopy: a retrospective cohort study. Am J Kidney Dis 2016;67:609-616.
XI. Markowitz GS, Bomback AS, Perazella MA. Phosphate enemas and GFR decline: it’s premature to sound the alarm. Kidney International 2016;90:13-15.
XII. Lochy S, Jacobs R, Honoré PM, et al. Int J Nephrol and Renovas Dis 2013;16:6: 61-64
XIII. Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med. 2003;163(7):803-808
XIV. Markowitz GS, Perazella MA. Acute phosphate nephropathy. Kidney Int 2009; 76:1027-1034.
XV. Hurst FP, Bohen EM, Osgard EM, et al. Association of oral sodium phosphate purgative use with acute kidney injury. J Am Soc Nephrol 2007;18:3192-3198.
XVI. Steven M, Brunelli MD. Association between oral sodium phosphate bowel preparations and kidney injury: A systematic review and metaanalysis. Am J of Kidney Disease 20095(3):448-456.
XVII. Alexander K Rocuts, Sushrut S Waikar, Mariam P Alexander, et al. Acute phosphate nephropathy. Kidney Int 2009;75:987-991.
XVIII. Hart E, Dunn T, Feuerstein S, Jacobs D. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy 2019;39(4): 443-453.
XIX. Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: understanding the associated risks and benefits of long-term use. Am J Health Syst Pharm 2023 Apr 8; 80(8):487-494.
XX. Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2015 Feb;87(2):458-64.
XXI. Valluri A, Hetherington L, Mcquarrie E, et al. Acute tubulointerstitial nephritis in Scotland. QJM 2015 Jul;108(7):527-32.
XXII. Fernández-Juárez G, Pérez JV, Caravaca-Fontán F, et al. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol 2018 Dec;13(12):1851-8.
XXIII. Nast CC. Medication-induced interstitial nephritis in the 21st century. Adv Chronic Kidney Dis 2017 Mar;24(2):72-9.
XXIV. Toto RD. Acute tubulointerstitial nephritis. Am J Med Sci 1990 Jun; 299(6):392-410.
XXV. Sánchez-Alamo B, Cases-Corona C, Fernández-Jarez G. Facing the challenge of drug-induced acute interstitial nephritis. Nephron 2023;147(2):78-90,
XXVI. Clarkson MR, Giblin L, O’Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004 Nov;19(11):2778-83.
XXVII. González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008 Apr;73(8):940-946.
XXVIII. Texeira Montezuma Sales G, Demarchi Foresto R. Drug-induced nephrotoxicity. Rev Assoc Med Bras 2020;66(1):S:82-S90.
XXIX. Mody H, Ramakrishnan V, Chaar M, Lezeau J, Rump A, Taha K, et al. A Review on drug-induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. Clin Pharmacol Drug Dev 2020 Nov;9(8):896-909.
XXX. Lim CC, Tan NC, Teo EPS, Kadir HBA, Kwek JL, Bee YM, et al. Non-steroidal anti-inflammatory drugs and risk of acute kidney injury and hyperkalemia in older adults. A retrospective cohort study and external validation of a clinical risk model. Drugs Aging 2022 Jan;39(1):75-82.
XXXI. Bakhriansyah M, Souverein PC, van den Hoogen MWF, de Boer A, Klungel OH. Risk of nephrotic syndrome for non-steroidal anti-inflammatory drug users. Clin J Am Soc Nephrol 2019;14:1355-1362.
XXXII. Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clin J Am Soc Nephrol 2022;17(8):1220-1233.
XXXIII. Fernández-Juárez G, Pérez JV, Caravaca-Fontán F, Quintana L, Shabaka A, et al. Spanish Group for the Study of Glomerular Diseases (GLOSEN). Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol 2018;13:1851-1858.
XXXIV. Lin JS, Mamlouk O, Selamet U, Tchakarov A, et al. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. OncoImmunology 2021;10:1877415.
XXXV. Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003;42(2):234-44.
XXXVI. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989;9(5):403-12.
XXXVII. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331(25):1675-9.
XXXVIII. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001;345(25):1801-8.
XXXIX. Wang K, Li X. Comparison of cardiorenal safety of nonsteroidal anti-inflammatory drugs in the treatment of arthritis: a network meta-analysis. Ann Transl Med 2022 Dec;10(24):1388
XL. Baker M, Perazella MA. NSAIDs in CKD: are they safe? Am J Kidney Dis 2020 Oct;76(4):546-557.
XLI. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008;78(6):743-750.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Diabetes
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
